11/01/2014 TGV-THERAPEUTICS’ MUL-1867-CF FOR CYSTIC FIBROSIS PATIENTS ACHIEVES POSITIVE RESULTS IN PILOT STUDY

New York, NY, November 01, 2014.  TGV-Therapeutics announces positive results from the  first-in-human pilot study of Mul-1867-CF in 15 cystic fibrosis patients during pulmonary exacerbation outside the US (in Russia).  Short-term administration of inhaled Mul-1867-CF improves pulmonary function, decreases the density of bacterial and fungal load in expectorated sputum, and reduces the need for oral and intravenous antibiotics and hospitalization. All patients showed clinical improvement and resolution of their acute respiratory exacerbation. The clinical assessments at day 5 and 14 demonstrated a significant difference in outcome and improvement of symptoms between pretreatment period.

It was shown that 14 days of Mul-1867-CF treatment compared with pretreatment period results in a markedly greater reduction in bacterial and fungal density in the lower airways and a higher frequency of eradication (as defined by no detectable microorganisms in culture). Treatment with Mul-1867-CF improved lung function during the study period.

 

About Lung Infections in Cystic Fibrosis Patients
Cystic fibrosis is an inherited, fatal disorder which affects the lungs and pancreas. It is marked by the production of abnormally viscous mucus resulting  in chronic respiratory infections. Bacterial and fungal respiratory infections are the main cause of morbidity and mortality in patients with cystic fibrosis. Currently there is no approved inhaled treatment for resistant bacteria and fungi in CF patients.

 

About TGV Therapeuticals
TGV-Therapeuticals is an innovative new pharmaceutical company developing novel pulmonary drugs. TGV Therapeutics’ lead product is Mul-1867-CF (novel drug candidate), the first inhaled antimicrobial being developed against multidrug-resistant bacteria and fungi in cystic fibrosis patients.